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ABSTRACT 
The skin is an important component of the human body, having crucial defensive, immune and 
sensory roles. Even though its barrier properties confer vital protection against the external 
environment, they also pose a great challenge for drug delivery. Disruption of skin barrier 
often leads to the formation of acute or chronic wounds that affect millions of patients 
worldwide. Moreover, due to its great surface area and ease of access, there are numerous 
compounds that can have detrimental toxicological consequences for human health. All these 
factors contribute to a growing need to study and understand skin behaviour, not only from an 
academic perspective, but also with great implications for industry and governments 
worldwide. Novel scientific and technological breakthroughs are improving predictive accuracy 
of skin in vitro models, which resulted in some of them gaining international acceptance 
worldwide. However, these models are often simplified, do not account for skin complexity 
and work in a low-throughput manner. Recently, microfluidic devices have emerged as novel 
methodologies to emulate biological functions. However, only a few skin emulative 
microfluidic devices have been developed so far, which only allowed limited types of assays to 
be performed. Therefore, this work was focused on the development and characterization of a 
novel material based on methacrylated hyaluronic acid (HAMA) and methacrylated pectin 
(PectMA) that could be used to create an in vitro skin model compatible with a high-
throughput skin microfluidic device. Material compositions with different HAMA/PectMA 
ratios and concentrations were evaluated envisioning the optimization of the system in terms 
of mechanical and biological performance. Increasing the concentration of HAMA or PectMA 
generated hydrogels with higher shear elastic moduli (G’). Indeed, mechanical performance 
was dependent on polymer ratios. When cultured with dermal fibroblasts, gels with 0.75% 
HAMA did not keep their integrity for the 7 days in culture, requiring the addition of a low 
PectMA concentration (0.125%). Mixed hydrogels with 0.75% HAMA / 0.125% PectMA 
appeared to promote cell clustering and a more elongated morphology than the remaining 
formulations. Polymer modification with cell-adhesive RGD peptides had a notable influence in 
cell behaviour, promoting cell spreading and leading to hydrogel disk contraction and the 
production of endogenous extracellular matrix, evidenced by the formation of a fibronectin 
network that was denser in hydrogels fabricated with higher RGD content. Together, these 
results suggest that soft hydrogel systems composed of HAMA and PectMA may become 
useful for the creation of in vitro skin models for skin organ-on-a-chip applications.    
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RESUMO 
A pele é um componente importante do corpo humano, desempenhando papéis cruciais a 
nível de defesa, imunitário e sensitivo. Apesar das suas propriedades de atuar como barreira 
conferirem proteção vital contra o ambiente externo, estas também se tornam num grande 
desafio para entrega de fármacos. A dirupção da barreira da pele leva por vezes à formação de 
feridas agudas ou graves que afetam milhões de pacientes mundialmente. Além disso, e 
devido à sua grande área de superfície e facilidade de acesso, existem vários compostos que 
podem levar a consequências tóxicas negativas para a saúde humana. Todos estes fatores 
contribuem para uma necessidade crescente de estudar e compreender o comportamento da 
pele, não apenas numa perspetiva académica, mas também a nível industrial e governamental. 
Recentes descobertas científicas e tecnológicas têm aumentado o poder preditivo de modelos 
de pele in vitro, resultando em alguns deles terem ganho aceitação internacional. No entanto, 
estes modelos são muitas vezes simplistas, não têm em conta a complexidade da pele e 
funcionam numa forma low-throughput. Recentemente, dispositivos de microfluídica têm 
surgido como novas metodologias para emular funções biológicas. No entanto, apenas alguns 
dispositivos deste género foram desenvolvidos para a pele, permitindo apenas a execução de 
um número limitado de ensaios. Assim, este trabalho foi focado no desenvolvimento e 
caracterização de um novo material baseado em ácido hialurónico metacrilado (HAMA) e 
pectina metacrilada (PectMA) que poderá ser usado para criar um modelo de pele in vitro 
compatível com um modelo de microfluidica high-throughput. Composições de materiais com 
diferentes rácios e concentrações de HAMA e PectMA foram avaliados com o intuito de 
otimizar o sistema a nível de propriedades mecânicas e biológicas. Aumentando a 
concentração de HAMA ou PectMA foi possível criar hidrogéis com maior módulo, mostrando 
uma dependência das propriedades mecânicas dos rácios poliméricos. Quando em cultura com 
fibroblastods da derme, géis com 0.75% HAMA não mantiveram a sua integridade durante os 7 
dias em cultura, requerendo a adição de baixas concentrações de PectMA (0.125%). Hidrogéis 
mistos compostos por 0.75% HAMA / 0.125% PectMA promoveram clustering celular e uma 
morfologia mais alongada do que as restantes formulações estudadas. Modificação dos 
polímeros com péptidos RGD que permitem adesão celular teve uma influência notável no 
comportamento celular, promovendo spreading celular e levando a uma contração dos discos 
e produção de matrix extracelular endógena, evidenciada pela formação de uma rede de 
fibronectina, mais densa em hidrogéis fabricados com maior conteúdo de RGD. Assim, estes 
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resultados sugerem que hidrogéis macios compostos por HAMA e PectMA podem vir a ser 
úteis para a criação de modelos de pele in vitro para aplicações organ-on-a-chip. 
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CHAPTER 1: INTRODUCTION 
The human skin is a vital agent playing important roles not only as a mechanical and chemical 
defence mechanism, but also as a relevant immune and sensory organ [1]. It is composed of 
three main layers: epidermis, dermis and hypodermis where multiple interactions take place 
between different cell types and structures [2]. Its singular properties give it a paramount 
barrier role, protecting the human body against external agents and preventing water loss [3]. 
However, even though its barrier properties are crucial for homeostasis, they pose a great 
challenge for drug delivery. Due to its easy accessibility and the fact that it allows to 
circumvent hepatic first-pass metabolism using relatively painless delivery systems, the skin 
has emerged as an important route for compound administration [4–6]. Therefore, strategies 
to overcome its barrier are now being the focus of multiple research efforts that often lead to 
the development of novel permeability enhancers that must not only be effective in 
overcoming the barrier but also safe to use [7]. 
On the other hand, skin barrier disruption can lead to the generation of acute or chronic 
wounds that have a great social and economic impact on the lives of millions of patients [8], 
making the discovery of new strategies towards improving wound repair and regeneration of 
paramount importance. There is a wide range of chemical substances and mixtures that can 
have detrimental toxicological consequences for human health through skin contact, thus 
requiring specific regulation and guidelines for their safety evaluation [9]. Advances in cell and 
tissue culture and engineering made possible to develop reliable in vitro methods to assess the 
behaviour of chemicals in contact with the skin [10–13]. The combination of cells, scaffolds 
and growth factors has led to the development of tissue engineered skin substitutes and novel 
advanced biomanufacturing strategies are now paving the way to the creation of more 
complex and biomimetic solutions [14]. Furthermore, due to their improved capacity to mimic 
biological systems, these methods are emerging as alternatives to in vivo animal studies, which 
are expensive and often fail to predict clinical results [15]. Even though simple in vitro cell 
culture studies are able to yield valuable information, more sophisticated systems are often 
required to model certain functions or properties [16]. In order for these systems to gain 
regulatory acceptance they should closely resemble in vivo skin behaviour, use standardized 
methodologies, and give reproducible and predictive results [17]. Internationally accepted 
methods are important and should be taken into consideration while developing novel model 
systems as these are accepted by academia, industry and governments for different 
applications such as classification and labelling of chemicals [9] and the testing of novel 
cosmetic products and formulations [18]. In the present chapter, the state-of-the-art of 
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current in vitro systems for transdermal transport, wound repair and cutaneous toxicity 
emulation will be revised, taking into consideration their compliance with international testing 
guidelines and current research needs. Advanced technologies, such as organ-on-a-chip 
models for skin applications, will be considered both in terms of their current features and 
upcoming potential to model skin functions and properties. 
 
1.1. IN VITRO ASSAYS FOR DRUG DELIVERY STUDIES 
Drugs or compounds can enter the human body through different routes. Overcoming the skin 
barrier is one of them as transdermal transport is usually painless, noninvasive [4] and avoids 
hepatic first-pass metabolism [5]. This makes it a valuable solution for drug delivery [19] and 
the study of cosmetics [20].  
When a substance contacts the skin, its fate is determined by phenomena such as diffusion, 
partitioning, metabolism, phase changes, adsorption and absorption [21] that, all together, 
originate distinct contributions to its behaviour in the human body. The effects of these 
processes, not only individually but also combined, and their interactions throughout the 
different skin layers, are not trivial to assess or simulate and, despite notorious developments 
in in silico modelling systems [22], in vitro and in vivo assays are still crucial to understand the 
behaviour and assess the safety of novel compounds and formulations in contact with the skin, 
as noted by worldwide accepted recommendations from the Organization for Economic Co-
operation and Development (OECD) [13,23]. In vivo models were the first to be established, 
having the advantage of providing information about the systemic behaviour of the 
substances, both in terms of kinetics and metabolism. However, they require the use of 
animals and radio-labelled compounds [24–26] and make the study of early absorption 
processes often difficult. Moreover, as animal skin has usually higher permeability than 
human, in vivo animal studies often overestimate percutaneous absorption [24]. 
In order to develop accurate and reliable in vitro transdermal transport models, it is first 
necessary to understand what happens to a compound when it contacts the skin and as it 
moves through the different skin layers, as well as how this process can be influenced by 
different skin properties. Then, it is necessary to understand how skin permeability can be 
modulated. Although passive diffusion through the skin is important for delivery of some 
drugs, the enhancement of transdermal transport by disruption of the skin barrier function has 
been gaining interest in the last decades [6].  
It has long been known that the top layer of the epidermis, the stratum corneum (SC), is the 
most important barrier to transdermal transport [27]. SC is composed of terminally 
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differentiated epidermal keratinocytes [28] and is characterized by having a “bricks and 
mortar” structure [29], with keratin-rich corneocytes acting as “bricks” embedded in 
extracellular hydrophobic “mortar” [30]. SC cell membranes have a higher lipid content 
compared to the whole tissue [31] and intercellular spaces that are rich in structural lipids 
having a prominent role in water retention [32,33] and acting as an entry barrier for non-lipidic 
or high molecular weight compounds [30]. Thus, the inability to hold water is often considered 
an indicator of barrier function impairment and increased susceptibility to external agents 
[34]. Skin barrier function is influenced not only by internal factors such as ageing [35] and 
circadian rhythms that influence skin pH, temperature and transepidermal water loss (TEWL) 
throughout the day [36], but also via external factors that are known modulators of SC 
properties. Here, pH has an effect on structural integrity and barrier function recovery [37]; 
relative humidity interferes with the mechanical properties [38]; high temperature leads to 
lipidic structural disorder and decreased resistance to water flow [39]; compounds such as 
fatty acids have been shown to increase fluidity, enhancing drug flux [40]; and alpha 
hydroxyacids contribute to maintaining skin barrier function against irritation [34]. After SC 
removal, the viable epidermis becomes the rate-limiting step to diffusion [41], making it 
relevant to study not only the influence of the SC, but also of the remaining skin layers in 
transdermal transport. 
Besides its diffusional barrier properties, skin also plays an important metabolic role. There are 
different enzymes which have metabolic relevance in human skin, contributing for Phase I and 
Phase II metabolism, as reviewed elsewhere [42,43]. The first-pass effect of the skin on 
topically applied compounds tends to be spatially confined and, in contrast with oral 
administration, is able to overcome hepatic enzyme reactions before entering circulation [43]. 
However, it is still important to consider metabolic effects when developing in vitro 
transdermal transport models as some compounds are modified while going through this 
barrier [44]. This can be accomplished with the use of viable tissue, with active 
biotransformation enzymes [44].  
One of the most well-known non-invasive drug delivery strategies is the use of transdermal 
patches, which were first introduced in the 1970s [19]. Currently, these are usually active for a 
period from one to seven days, being applied to deliver compounds such as clonidine, 
estradiol, fentanyl, lidocaine, nicotine, nitroglycerine, scopolamine and testosterone for 
applications in cases of hypertension, birth control, hormone replacement, among others 
[19,45]. However, as skin poses a significant barrier to the transport of many compounds of 
interest, different methodologies to overcome this problem have been developed in the last 
decades [6]. Not only the use of strategies such as chemical enhancers [46] like fatty acids [40], 
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fatty alcohols [47], surfactants and microemulsions [48], but also more sophisticated 
techniques such as ultrasounds [49] and microneedles [50] have been shown to increase skin 
permeability. Moreover, combinations of different chemical enhancers [7] or enhancing 
techniques have been observed to act synergistically [51], making combinatorial screenings a 
promising approach for improving transdermal transport avoiding skin irritation [7].  
 
 1.1.1. IN VITRO TRANSDERMAL TRANSPORT AND SKIN BARRIER FUNCTION MODELS 
 In vitro studies are crucial for primary evaluation of novel compounds or formulations that 
contact the skin. The OECD guidelines for testing chemical compounds recommend the use of 
diffusion cell assays to investigate transdermal transport. This type of setup consists in a 
human or another animal skin sample between a donor and a receptor chamber. The test 
substance is applied on the surface of the skin and left for a period of time, followed by 
appropriate removal. Evaluation of the substance or its metabolites can be performed in the 
receptor fluid, even though it is also important to consider the amount remaining absorbed in 
the skin [13]. Moreover, these assays can be performed in steady state, with an infinite dose or 
non-steady state, with finite doses. Even though it is possible to extract relevant information 
from steady-state assays, finite dose studies are usually closer to what happens during real 
human exposure [52].  
In order to evaluate skin integrity prior to absorption studies [24] and to assess the effects of 
techniques that modulate skin permeability, in vitro model systems that are capable of a 
robust evaluation of in vitro skin barrier function are necessary. This property can be analyzed 
in vitro with techniques such as tritiated water flux  [53], evaporimetry [53] and electrical 
resistance measurements [54]. Tritiated water (T2O) flux measures skin permeability to 
radioactive water. T2O is applied on the epidermis and travels across the skin, being collected 
and evaluated for radioactivity after barrier transposition [53]. On the other hand, 
evaporimetry has been applied to measure TEWL, an indicator of skin water-holding capacity 
[34,53]. However, as this process is not only dependent on water diffusion through the skin 
but also on its evaporation and partitioning at SC surface, factors such as environmental 
relative humidity, temperature or air flow may come into play [53,55]. Therefore, correlations 
between TEWL and measures of T2O flux have been performed in some cases [53,56]. Finally, 
skin electrical resistance measurements have also been pointed out as alternatives to evaluate 
skin integrity in vitro. Resistance can be quantified by applying a fixed current between two 
electrodes across a skin sample. This is a safe and faster method that can be used with in vitro 
diffusion chambers [54].  
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Regarding the choice of skin source, viable human skin obtained from autopsies or cosmetic 
surgery is the current gold standard for transdermal transport studies [57]. Yet, its availability 
is limited and a high variability is usually observed between donors in terms of age, gender and 
race [58]. For in vitro assays, fresh [59] or previously frozen [53] samples can be used. 
However, even though the latter may be a more convenient option, the freezing and thawing 
process may lead to tissue necrosis [59]. Fresh and frozen human skin may show similar 
permeability coefficients to water absorption [60], but behave differently for permeation of 
other compounds [59]. Moreover, the freezing process may inactivate a number of 
biotransformation enzymes [59], while others stay active [61]. Therefore, and depending on 
the compound in study, the use of fresh skin may be recommended. 
Contrary to skin from human subjects, animal skin presents higher availability and 
controllability control in terms of donor age and gender [58]. Some of the most commonly 
used animal skin sources are rodents [62,63], rabbits [25] or pigs [25,62–64]. Rat skin 
permeation rate and concentration have been reported to be of the same order of magnitude 
as human skin for some topically applied substances with a wide polarity range (salicylic acid, 
hydrocortisone, clotrimazole and terbinafine) [62] but higher permeation has also been 
verified for compounds such as hydrocortisone [62] and paraquat [63,65], among other 
substances. Nevertheless, after comparative percutaneous absorption in vitro studies using 
diffusion cell assays, pig skin has been considered the closest in vitro alternative to human skin 
[62,63] and it has shown better performance than rat skin in particular for permeability levels 
of lipophilic compounds [63]. 
Besides human and animal skin, it is also possible to evaluate transdermal transport using in 
vitro human skin equivalents (HSE) that can either be composed of SC and viable epidermis as 
reconstructed human epidermis (RHE) models, or include an additional dermal layer as full-
thickness (FT) models [66]. This type of in vitro models exhibit reduced variability but tend to 
have enhanced permeability levels when compared to human or pig skin ex vivo [66]. 
Moreover, as this kind of constructs usually lack skin appendages such as hair follicles, they 
may not be suitable for studying transport phenomena such as follicular penetration [67]. 
 
1.1.1.1. LOW-THROUGHPUT MODELS 
 Transdermal transport studies in vitro are usually performed with diffusion chambers. Franz 
Diffusion cells (Figure 1a) are static models that were introduced in 1975 as a way to replicate 
percutaneous absorption [68] and are now commercially available with a widespread use 
[41,69]. Their design consisted in skin samples placed over an O-ring ball joint separating two 
parts of a glass chamber. The epidermal side was exposed to air while a buffer solution was in 
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contact with the dermal portion. The dermal solution was under magnetic agitation and 
controlled temperature conditions and could be removed, replaced and analysed at different 
time points during the transdermal transport assays [68]. Even though this model was 
versatile, allowing infinite [70] and finite [68] dose studies, it did not allow a continuous 
perfusion of the sample and required large volumes of skin. 
 
 
Figure 1:  Transdermal transport models; (a) Franz diffusion cell; (b) Flow-through diffusion cell; (c) High-
throughput transdermal transport model using plates with an array of orifices; (d) High-throughput 
transdermal transport model using paraffin to isolate different skin portions; Legend: A: test compound; 
B: skin sample; C: receptor fluid; D: temperature regulating fluid; E: paraffin; F: ATR-FTIR crystal. 
Flow-through diffusion cells (Figure 1b) were then developed, using a perfused fluid under the 
skin surface flowing with a defined rate. Identically to blood flow, the receptor fluid was 
constantly renewed, which made this strategy more biologically relevant for the study of 
compounds with limited solubility and allowed automatic sample collection making it more 
convenient for constant monitoring [71]. 
 
 1.1.1.2. HIGH-THROUGHPUT MODELS 
The wide range of potential skin permeability enhancement strategies that can be applied 
alone or in combination to study transdermal delivery of different compounds makes it 
necessary to transition from conventional models to novel high throughput strategies. 
Conventional methodologies such as Franz diffusion cells are not compatible with high 
throughput screening since they require large skin areas and time-consuming sample setup 
and manipulation [46]. A high throughput method for up to 100 assays was developed allowing 
a 50-times higher efficiency in skin usage when compared with a Franz diffusion cell (Figure 
1c). The model was based on two plates fixed to each other using four screws. The plates were 
drilled with an array of 100 (10x10) 3 mm orifices that acted as wells separated by a skin 
sample placed with the SC facing the donor plate and dermal side exposed to phosphate 
buffered saline (PBS) solution in the receiving plate. For validation, skin permeability was 
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challenged with chemical enhancers and evaluated with conductivity measurements [46]. This 
model has since been successfully applied to screen for synergic combinations of 32 different 
chemical enhancers as more than 5,000 formulations [7]. Even though it has shown promising 
results, permeability assessment has not been automatized. 
Another strategy has been applied to study multiple formulations simultaneously in the same 
skin sample, using a paraffin automatic dispenser that was able to draw 16 octagonal wells 
with 2.4 mm diameter on a skin sample (Figure 1d). These wells acted as impermeable barriers 
containing different solutions that were manually applied with a pipette. Samples were further 
analysed with attenuated total reflectance-Fourier transform infrared (ATR-FTIR) imaging to 
measure the permeation of 4-cyanophenol, making it possible to study the over-time 
permeation of this compound in 12 samples simultaneously  [72]. 
High-throughput strategies often require miniaturization. However, even though they may 
lead to a higher time efficiency while using a smaller skin area per sample, they open new 
challenges due to changes in permeability as a consequence of the decreasing skin-compound 
contact area. It has been described that, while using an array of donor reservoirs of different 
radii, skin permeability to mannitol decreases with increasing contact area [73].  
Despite the great advantages of both models discussed above there seems to be considerable 
room for improvement. They both require considerable manipulation and, as they perform 
several assays on a single skin sample, using these techniques further scale-down may lead to 
cross-contamination between different assays due to lateral compound diffusion within the 
sample. 
 
1.2. IN VITRO ASSAYS FOR WOUND HEALING STUDIES 
Skin wounds can be classified as acute or chronic. Acute wounds often follow an organized 
reparative process while chronic wounds are usually not able to restore most of their anatomic 
and functional features [74]. Wound healing is a complex process requiring the interplay of 
several different agents. This process is composed of three major phases: coagulation and 
inflammation, new tissue formation and tissue remodelling [75,76]. The coagulation and 
inflammation phase are first characterized by the formation of a fibrin plug. This structure is 
composed of platelets embedded in a matrix of fibrin and other proteins, promoting 
haemostasis and providing temporary wound closure [77], while acting as a scaffold for new 
tissue formation and being a reservoir of chemokines and growth factors [78]. These soluble 
compounds are released from the injured site and recruit circulating inflammatory cells such as 
neutrophils and monocytes in order to clear and remove tissue remnants from the wounded 
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area [77]. During the following phase, the formation of new tissue, keratinocytes migrate, 
proliferate and maturate over the disrupted dermis, contributing to the restoration of skin 
epithelial barrier function properties [76]. This process of wound re-epithelization is of great 
importance and its malfunction may lead to the generation of chronic wounds. Its regulation is 
achieved by a range of soluble factors and surface protein interactions [79] combined with 
physical stimuli, such as electric fields promptly generated after skin epithelial disruption and 
condition keratinocyte migration [80]. In addition, endothelial cells form new blood vessels by 
angiogenesis and some capillaries colonize the fibrin clot, giving rise, along with macrophages 
and fibroblasts, to granulation tissue rich in collagen type III. Finally, macrophages stimulate 
fibroblast differentiation into a myofibroblast cell type with contractile activity, promoting 
wound closure [76]. The last phase, tissue remodelling, is characterized by a decrease in 
cellular activity, apoptosis at the wound site and extracellular matrix (ECM) remodelling by 
secreted matrix metalloproteases (MMPs), degrading type III collagen that is then replaced by 
type I [76,81]. 
Since skin wounds result in a considerable societal burden and economic impact [8] research 
towards a better understanding of wound healing is of paramount importance to generate 
new strategies to enhance wound repair and regeneration. 
 
1.2.1. IN VITRO WOUND HEALING MODELS 
1.2.1.1 LOW-THROUGHPUT MODELS 
Wound repair studies can be performed in vitro using bidimensional (2D) or tridimensional 
(3D) skin models. While 2D models, focused on simple aspects of wound repair, are often 
easier and simpler to be performed, more complex 3D models better mimic tissue 
microenvironment and allow the study of a wider range of phenomena [82,83]. Different 
assays have been developed allowing the study of chemical agents [83] or physical stimuli, 
such as the influence of electric fields [84] or shear stress [85]. 
A simple 2D model approach developed to emulate wound repair is the in vitro scratch test 
(Figure 2 a). This affordable strategy to evaluate cell migration consists on the creation of a 
“scratch” on a confluent cell monolayer, followed by observation of cell migration from the 
edges of the gap towards its centre, in a process mimicking wound closure. While using a very 
basic approach, it has allowed continuous monitoring of the samples with time-lapse 
microscopy as well as evaluation of single cell migration [83]. An alternative to mechanical 
wounding studies has been developed using barrier migration assays (Figure 2d) where, 
instead of disrupting a cell monolayer, a wound model was created through the use of a 
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physical barrier insert that did not allow cell colonization of a certain area. Once that barrier 
was removed, cells moved over an unaltered surface, making it possible to evaluate cell 
migration using microscopy techniques [86]. 
A different strategy relies in studying cell migration through a membrane. This has been done 
through the use of the Boyden chamber assay that was proposed in 1962 as a way to study 
leucocyte chemotaxis (Figure 2f). A device composed of two compartments separated by a 
filter membrane was loaded with a cell suspension in one side and a test solution on the other. 
After incubation and membrane removal from the chamber, it was possible to assess cell 
migration using microscopy techniques to observe the number of cells that went from one 
compartment to the other through the filter [87]. Modifications of this technique have since 
been used in skin wound repair studies to evaluate the effect of both chemotactic promoters 
[88] and inhibitors [89].  
On the other hand, 3D wound models can be created using scalpels [82,90], skin meshers [90], 
freeze damage [91] and laser irradiation [92]. These models are able to emulate wound repair 
in a more in vivo-like environment, allowing for a more complex study of biological processes. 
For instance, after scalpel incisional or excisional wounding of HSE constructs, it was possible 
to transfer them to the top of a collagen gel where they were kept at the air-tissue interface, 
and to observe keratinocyte migration, restoration of epithelial integrity, wound closure and 
stratification [82]. However, most wounding strategies require extensive tissue manipulation 
[82,90,91]. One way to reduce the need for manipulation while reproducibly creating wounds 
is to use laser irradiation. With this strategy, it was possible to control the magnitude of the 
damage by varying the number of laser pulses applied, affecting the epidermis alone or in 
combination with the dermis, creating reliable model wounds [92]. 
 
 1.2.1.2. HIGH-THROUGHPUT MODELS 
High-throughput systems have been developed not only for assessment of cell migration on 
flat surfaces [93] but also through a membrane [94].  
A variation of the in vitro scratch test has been used for high-throughput analysis in a 384-well 
plate (Figure 2b). Cell monolayers were disrupted by a manually operated 96 array of pins, 
resulting in wounds of similar morphology in different wells that could be evaluated using 
fluorescence microscopy and automated image analysis [93]. More recently, a miniaturized 
system with high scale-up potential was used to evaluate cell migration. This method applied a 
laminar flow of trypsin to generate a wound model, promoting cell detachment and creating a 
gap in a fibroblast monolayer (Figure 2c). This system allowed the creation of wounds models 
with well-defined shape and edges and the study of the influence of different compounds on 
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fibroblast migration using a phase-contrast microscope [95]. In addition, the development of 
an integrated system was achieved using laser pulses to create wound models in 96-well cell 
cultures (Figure 2e). This high-throughput system used an automated mechanism for wound 
generation and image capturing at different time points after wounding. Following image 
analysis, wound area could be determined and wound healing levels estimated over time, 
making it possible to evaluate the closure of irregular-shaped wounds with no need for sample 
fixation and in a fast, high-throughput manner [96]. 
 
Figure 2: In vitro wound healing models. (a) In vitro scratch test using a micropipette tip; (b) In vitro 
scratch test using an array of pins; (c) wound model formation with a laminar flow of trypsin flanked by 
laminar flow of pbs; (d) barrier migration assay; (e) wound model formation with laser irradiation; (a-e): 
wounding and wound closure mechanisms. After wound formation, cells migrate towards the wounded 
area; (f) Boyden chamber assay. 
Furthermore, a system using a modified Boyden chamber assay (Figure 2f) has also been 
applied to study cell migration and chemotaxis through a porous membrane in a 96-well 
format. By using a fluorescent staining of cell nuclei, the number of migrated cells was 
calculated through the use of an automated microscope and software analysis [94]. These 
novel methodologies, driven by advances in miniaturization, automation and image analysis 
are making it possible to create model systems that allow a simultaneous quantitative 
evaluation of multiple samples, contributing to advances in high-throughput screening of 
different potential wound repair modulators. 
 
1.3. IN VITRO ASSAYS FOR SKIN TOXICITY STUDIES 
Different substances and mixtures can have detrimental health consequences. Therefore, a 
classification and labelling system has been established by the United Nations. Health hazards 
11 
 
due to skin contact can be divided in toxicity, corrosion, irritation, and sensitization. It is 
possible to categorize substances or mixtures based on their acute toxicity using dermal Lethal 
Dose, 50% (LD50) levels, which is the amount of a chemical necessary to kill 50% of a 
population of test animals. Skin corrosion and irritation are related to the generation of skin 
damage up to four hours after application of a test substance. Indeed, corrosion leads to 
irreversible damage, with visible necrosis in the epidermis and dermis, whereas irritation leads 
to reversible damage. A skin sensitizer is a substance that leads to an allergic response after 
contact with the skin. These classification systems are mainly based on animal studies and 
clinical information. However, other parameters such as pH and in vitro tests may also be 
considered in some cases [9], such as the ones recommended by the OECD for assessment of 
skin corrosion [12,97,98] and irritation [10]. Moreover, as the European Union Cosmetics 
Regulation has put a ban on animal testing and requires studies of the toxicological profile of 
the substances present in cosmetic products, studies related to skin irritation, sensitization and 
in some cases photo-induced toxicity are required for these cases [18]. Other studies such as 
genotoxicity can also become relevant [99] and the OECD has issued guidelines for its in vitro 
assessment [100]. 
Skin corrosion can be evaluated in vitro by measurements of transcutaneous electrical 
resistance (TER), a parameter that evaluates SC integrity and barrier function as recommended 
by OECD guidelines. After application of a test chemical on the surface of a skin disk placed 
inside a testing apparatus, TER should be evaluated after 24 hours and compared with 
standardized values. A corrosive effect is noticeable by a decrease of TER below a threshold 
level [97]. Even though this method recommends the use of rat skin [97], it is also possible to 
identify corrosive substances and mixtures using RHE models composed of non-transformed 
epidermal keratinocytes. A range of RHE commercially available models such as the EpiSkin®, 
EpiDerm®, SkinEthic® and epiCS® are recommended for different categorization levels. These 
models are required to offer a viable multi-layered epithelium under a functional SC with 
validated barrier function, morphological properties and reproducibility. This method 
considers corrosive chemicals as those that are able to diffuse through or erode the SC and 
have cytotoxic effects on cells in the underlying layers [12]. These effects are evaluated by 
measuring cell viability immediately after chemical exposure using in vitro metabolic activity 
assays, as the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) enzymatic 
conversion assay [12]. In addition to these methods, corrosion can also be assessed through 
the evaluation of the amount of damage inflicted by a chemical to artificial membranes that 
behave similarly to animal skin. Here, corrosion can be evaluated by color change of a chemical 
detection system after penetration through the barrier [98]. However, these methods can only 
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evaluate skin corrosion and are not able to distinguish skin irritants from chemicals that do not 
require classification [101]. Therefore, in vitro assessment of skin irritation is recommended by 
OECD guidelines and can be evaluated with RHE models, using a different protocol from 
corrosion evaluation, both in terms of exposure time and post-treatment incubation before 
MTT assay [10].  
Cell metabolic activity studies using techniques such as MTT and alamar blue assays have been 
carried out in a high-throughput manner for the assessment of cytotoxicity of different 
compounds using an automated liquid handling system in 96-well plate cultures. However, 
these studies have used traditional 2D cell culture methodologies [102] instead of the 
recommended RHE cultures. It is, however, possible to apply low-throughput cell metabolic 
activity assessment techniques using RHE after a primary high-throughput assessment, as 
performed in a study of skin permeability enhancers in which only the most promising 
enhancers were screened for their irritation potential [7]. It is therefore necessary to develop 
reliable and scalable high-throughput methodologies compliant with OECD guidelines for in 
vitro assessment of skin irritation and corrosion.  
Skin sensitization can be assessed in vitro with the KeratinoSens™ ARE-Nrf2 Luciferase test 
method. By using an immortalized human keratinocyte cell line that expresses luciferase after 
exposure to small electrophilic test substances such as skin sensitizers, this assay is able to 
evaluate a key biological event related to skin sensitization by the induction of a specific cell 
signalling pathway. The induction of the luciferase gene can then be quantified by 
luminescence detection [11]. This assay is suitable for high-throughput screening but its use 
alone is not sufficient for the assessment of skin sensitization, something that can only be 
thoroughly evaluated in combination with other testing methodologies. Some of the suggested 
techniques are comparisons with chemical analogues, the study of chemical reactivity with 
peptides or proteins, dendritic cell activation studies and in silico models [11,103–105]. 
Genotoxicity can be evaluated according to OECD guidelines using the in vitro micronucleus 
test. This method is used to investigate the effect of a chemical on cell division through the 
detection of chromosomal damage that was transferred to daughter cells [100]. This strategy 
has been applied for studying micronucleus formation with the EpiDerm™ RHE in a multi-
laboratory study and suggested as a reliable assay for the study of cosmetic genotoxicity [99]. 
Cutaneous toxicity is a complex process and even though there have been significant 
improvements on in vitro methodologies for its evaluation, only a few protocols have been 
proven to be robust enough to gain recommendation in international guidelines. Moreover, 
these recommended methods acting alone are often not enough to gain a complete 
understanding of skin toxicity. Therefore, and according to the current shifting trend from in 
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vivo to in vitro methods in domains such as the testing of cosmetics, it is necessary to develop 
novel, integrative testing platforms for the assessment of skin toxicity that are reliable, 
versatile and can be implemented in multiple laboratories. 
 
1.4. MICROFLUIDIC STRATEGIES FOR SKIN EMULATION 
Due to the current needs for the development of more biologically relevant platforms for in 
vitro studies, the organ-on-a-chip concept has been proposed and described as a device that 
aims to model the physiological functions of tissues or organs through the use of cell culture in 
continuously perfused microfluidic systems [16]. These systems consist of microfluidic 
chambers where one or more cell types are usually cultured, and that can further be separated 
by porous membranes mimicking biological interfaces [106]. Moreover, it is possible to include 
biologically-relevant forces in the system such as peristalsis-like deformations and shear stress 
as well as to establish co-culture systems with microorganisms [107] in order to modulate cell 
and tissue behavior. Microfluidic devices for emulation of organs such as the lung [106], kidney 
[108,109], liver [110], bone marrow [111], gut [107,112] and skin [113,114] have been 
developed by different research groups in the past decade, with significant progress. These are 
versatile models that can be based on in vitro [106] or ex vivo [111] culture systems not only 
for recapitulation of biological features and processes [112] but also as pathophysiological 
models of disease [107,115]. 
 
 
Figure 3: Microfluidic systems: (a) increasing channel width leads to an increasing flow rate; (b) 
decreasing channel length leads to an increasing flow rate; 
Even though considerable research efforts have been focused on emulating different organs, 
only a reduced number of skin microfluidic systems have been developed so far, as 
summarized in Table 1. However, these are based on a wide variety of tissue models, from 
keratinocyte [116] or fibroblast [85,117,118] cultures to human skin equivalents [113,114] or 
ex vivo tissue [119–121] and have been applied for the study of processes such as transdermal 
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transport [113], wound healing [85] or to assess the response to shear stress [85,114,116–
119], chemical agents [113,118–121] or electrical stimuli [85].  
Early skin microfluidic devices were developed as simple models consisting of a flat glass 
surface in contact with polydimethylsiloxane (PDMS)-patterned microchannels fabricated by 
silicon photolithography and micromolding. Multiple-channel configurations were designed 
and the same pressure drop in channels of distinct widths was applied (Figure 3a) [117,118], 
allowing the over-time study of a range of linear [118] or logarithmically [117] increasing flow 
rates on fibroblast cell morphology [117] and detachment [118]. The first microfluidic model 
with human keratinocytes was designed to provide a range of shear conditions to cells 
cultured over a collagen-patterned surface. Channels were designed with different lengths, 
resulting in a linear flow rate increase (Figure 3b). This strategy allowed light microscopy 
analysis for cell morphology assessment, on-chip immunostainings and cell viability 
quantification using fluorescence microscopy [116].  
A device allowing multiple laminar flows over a surface was produced and used to create a 
microfluidic wound healing model (Figure 2c). By using three inlets, a flow of 
trypsin/ethylenediaminetetraacetic acid (EDTA) could be established between two flows of 
PBS over a fibroblast monolayer, allowing the detachment of a well-defined cell portion. 
Afterwards, cell migration towards the centre of the wound was evaluated by microscopy 
under the influence of chemical migration promoters and inhibitors [95]  
Recently, more sophisticated approaches have been developed to combine media perfusion 
and electrical stimuli on fibroblast cell cultures [85,122]. A microfluidic system for wound 
healing studies was fabricated in order to assess the effect of chemical and electrical stimuli on 
fibroblast migration. This chip was composed of a polymethyl methacrylate (PMMA) channel 
for medium flow and electrical stimulus attached to a tissue culture polystyrene (TCPS) dish for 
cell culture. A wound healing model was established with a modified barrier assay observed 
with time-lapse imaging. The electrical field inside the chip was measured in a non-invasive 
way using a Dermacorder (BioElectroMed Corp.) [122]. A different system was also developed 
to study the influence of fluid shear stress in combination with an electrical field stimulation 
on fibroblast cell cultures inside PDMS microchannels. This platform allowed the application of 
sequential or combinatorial stimuli with a peristaltic pump and a voltage source as well as real-
time monitoring by optical microscopy and channel voltage measurements. Using this system, 
it was possible to establish an in vitro wound healing model and to find a cooperative effect of 
the two physical stimuli in study on fibroblast migration rate and direction [85]. 
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Table 1: Types of assays that have been performed on-chip using skin microfluidic devices. 
Stimulus Skin model On-chip assay Ref. 
Shear stress, chemical 
substance in culture 
medium (EGF) 
WT NR6 mouse 
fibroblasts 
Observation with inverted 
microscope 
[118] 
Shear stress 
3T3 mouse fibroblast 
culture 
Observation with inverted 
microscope 
[117] 
Shear stress KC 
Observation with inverted 
light and fluorescence 
microscope, live/dead assay 
and immunostaining 
[116] 
Chemical substance in 
culture medium (fetal 
bovine serum, 
phalloidin, cytochalasin 
D, rat epidermal growth 
factor) 
3T3 mouse fibroblast 
culture 
Wound formation and cell 
migration, observation with 
phase contrast inverted 
microscope 
[95] 
Electric field chemical 
substances (serum, β-
lapachone) 
3T3 mouse fibroblast 
culture 
Observation with inverted 
microscope 
[122] 
Shear stress and electric 
field 
DFC 
Observation with phase 
contrast inverted microscope 
[85] 
Shear stress SB, HSE Skin sample collection [114] 
FAM-Tagged nucleotide 
solution on topical 
surface 
HSE Medium collection [113] 
Chemical substance in 
culture medium 
(doxorubicin) 
HSE Skin sample collection [113] 
Chemical substance in 
culture medium 
(troglitazone) 
SB + liver microtissue 
aggregates 
Skin sample and medium 
collection 
[119] 
Shear stress 
SB + liver microtissue 
aggregates 
Skin sample and medium 
collection 
[119] 
Chemical substance in 
culture medium 
(troglitazone) 
SB + liver microtissue 
aggregates + 
endothelial cells 
Skin sample and medium 
collection 
[121] 
Chemical substance in 
culture medium 
(troglitazone) 
SB + liver microtissue 
aggregates + intestine 
+ kidney 
Skin sample and medium 
collection 
[120] 
 
DFC: Dermal fibroblast culture; EGF: Epidermal growth factor; KC: Keratinocyte culture; HSE: Human skin 
equivalent; SB: Skin biopsy. 
In order to integrate 3D human skin equivalent models or skin biopsies in microfluidic systems, 
different skin-on-chip devices have been recently developed. A Multi-Organ-Chip (MOC) 
system allowing culture of different tissues in different compartments under static or dynamic 
conditions was fabricated with an on-chip pulsatile micropump to generate fluid flow (Figure 
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4a). This system was used to study a FT skin in vitro model (EpiDermFT®) cultured over a 
subcutaneous tissue biopsy as well as the behaviour of ex vivo skin and ex vivo single hair 
follicular units. The versatility of this device allowed not only submerged tissue culture but also 
the use of Transwell® systems integrated within the chip with skin at the air-liquid interface 
[114]. The same system was applied in a more integrative approach by combining tissues from 
multiple organs on the same chip as a co-culture system. Skin biopsies at the air-liquid 
interface were co-cultured in a two-organ-chip system with liver tissue [119,121] and in a four-
organ-chip system with liver, intestine and kidney tissues for up to 28 days [120]. An 
innovative pumpless skin-on-chip device was also recently fabricated (Figure 4b), allowing the 
study of FT human skin equivalents at the air-liquid interface for up to three weeks. This 
system has been used not only for drug testing with histology and immunohistochemistry 
studies after skin sample removal but also for transdermal transport studies after medium 
collection. Moreover, in contrast to the MOC system, it was possible to control the medium 
flow rate with no need of a pump, by placing the chip on a rocking platform. Even though this 
strategy made it difficult to maintain the air-liquid interface at the skin sample surface, it may 
allow for an easier scale-up for testing a higher number of samples simultaneously, as it does 
not require pump and tubing systems for each sample  [113]. 
 
 
Figure 4: 3D skin microfluidic devices. (a) multi-organ-chip (adapted from [123]); (b) pumpless skin-on-
chip (adapted from [113]); A: injection port; B: on-chip micropump; C: skin sample at the air-liquid 
interface on Transwell® system; D: skin sample submerged in circulating fluid; E-F: medium reservoirs; 
G: skin sample at the air-liquid interface on a membrane. 
On-chip platforms for skin emulation have been proven to be versatile alternatives for the 
evaluation of different biological phenomena. Moreover, as they are more sophisticated than 
earlier in vitro models, they make it possible to study the combination of different stimuli and 
can be designed to be used with a wide range of skin models. However, most skin-on-chip 
devices using 3D culture methods similar to the ones recommended by international 
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guidelines only allow basic on-chip assays, providing skin or medium sample collection ability 
and requiring off-chip analysis. Even though some miniaturization and process automation has 
been accomplished, in order to develop high-throughput on-chip systems, less manipulation 
and more integration of testing methodology are required. Recently, novel strategies 
combining advanced high-throughput and organ-on-a-chip technologies [124,125] in 
combination with 3D bioprinting [124] have been reported, potentially contributing to the 
creation of novel skin-on-chip platforms. However, testing reliability and reproducibility still 
have to be proven in order to possibly include on-chip assays in international testing 
guidelines. Even though microfluidic devices may allow a more comprehensive emulation of 
biological events, it is necessary to find a balance between complexity and simplicity in order 
to make these systems easy to use and compatible with both research and regulatory needs.  
However, even though plenty research efforts have been put in place for the development of 
organ-on-a-chip models, from our knowledge, only two systems integrating microfluidic 3D 
skin constructs have been developed so far. These were fairly simple systems, optimized for 
only one skin sample and posing several difficulties to scale up. However, as novel 
technologies combining high-throughput, organ-on-a-chip, and advanced fabrication 
technologies such as 3D bioprinting have been recently developed [124,125], it is now possible 
to create novel and more versatile devices for skin emulation. 
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CHAPTER 2: OBJECTIVES 
In order to develop a skin-on-chip device useful for emulating phenomena such as transdermal 
transport, wound repair and skin toxicity in a high-throughput manner, the work performed in 
the scope of this thesis was focused on the production of a 3D in vitro skin model. This model, 
composed of fibroblasts entrapped in a photopolymerizable hydrogel system based on 
methacrylated hyaluronic acid (HAMA) and methacrylated pectin (PectMA), was aimed to be 
used as the dermal component of the device. 
 
In order to successfully produce and integrate this skin model as part of the organ-on-a-chip 
system, several requirements need to be fulfilled, including: i) suitability for high-throughput 
applications, particularly in 96-well plate arrays; ii) possibility of being used as a 
photopolymerizable bioink for 3D printing to create structural complexity and allow 
automated fabrication of reproducible constructs; iii) ability to sustain fibroblasts in culture for 
several days, keeping them viable and metabolically active. 
 
Therefore, and in order to design and produce a suitable skin model, the main objectives of 
this thesis were:  
1. To purify and chemically modify biocompatible polymers, namely hyaluronic acid and 
pectin, to allow the development of a photopolymerizable hybrid hydrogel system; 
2. To prepare and characterize hydrogel formulations with varying polymer compositions 
and ratios, envisioning the tunability of the mechanical properties of the developed 
system; 
3. To functionalize the proposed materials with RGD peptides to provide the hydrogels 
with cell adhesive cues;  
4. To evaluate the in vitro response of fibroblasts cultured within the hydrogel matrices, 
in terms of cell viability and ability to spread inside the hydrogels; 
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CHAPTER 3: MATERIALS AND METHODS 
3.1. MATERIALS 
Hyaluronic acid sodium salt (HA, Hyasis® 850P, Mw = 1.6 MDa) was obtained from Novozymes; 
Low-methoxyl (LM) citrus pectin (Classic CU701) was provided by Herbstreith & Fox. 
Methacrylic anhydride (MA, 276685) and 2-Hydroxy-4′-(2-hydroxyethoxy)-2-
methylpropiophenone (Irgacure 2959) were purchased from Sigma. 
3.2. PECTIN PURIFICATION 
A 1% (w/v) LM pectin solution was prepared by dissolution in Hyclone™ endotoxin-free cell 
culture grade water (GE Healthcare). After dissolution, pH was adjusted to 6 and the solution 
was filtered using a succession of 0.8 μm, 0.45 μm and 0.22 μm mixed cellulose ester filter 
membranes (Millipore). Then, 2% (w/v) activated charcoal (Sigma) was added and the 
suspension was agitated (250 rpm) for 1h at room temperature and centrifuged at 60 000 g for 
1h at 20oC (Beckman Avanti J-26 XP, Beckman Coulter). After discarding the supernatant, 
suspensions were ultracentrifuged at 120 000 g for 1h at 20oC (Beckman Optima, Beckman 
Coulter), decanted and filtered with 0.22 μm polyethersulfone filter membrane using a bottom 
top vacuum filter unit (Millipore). Finally, the resulting purified pectin solutions were frozen at 
-20oC, freeze-dried for 2 days (BenchTop Pro, VirTis) and stored at -20oC until further use. 
3.3. SYNTHESIS OF METHACRYLATED HYALURONIC ACID 
HA was methacrylated based on previously established protocols [126,127]. Briefly, HAMA was 
synthesised by reacting a 1% (w/v) HA solution prepared in tris-buffered saline solution (TBS, 
100 mM Tris, Amresco, 150 mM NaCl, VWR, pH 8) with a 43-fold molar excess of MA. The 
mixture was allowed to react for a total of 6h under magnetic stirring with stepwise additions 
of MA (37.5% of total MA volume at 0h, 37.5% at 1.5h and 25% at 3h). This reaction was 
performed in an ice bath and pH was maintained at 8-8.5 by dropwise addition of a 5M sodium 
hydroxide (NaOH) solution (VWR). HAMA was then precipitated and washed in ethanol at 4oC, 
left to dry for 1h and re-dissolved overnight in deionized water. The obtained HAMA solution 
was purified by dialysis (MWCO 3.5 kDa, Spectra/Por®, Spectrumlabs) against decreasing 
concentrations (7.5, 6.25, 5, 3.75, 2.5, 1.25, 0 g/L) of sodium chloride (NaCl) in deionized water 
for two days, with water renewal 3 times a day. The HAMA solution was then frozen at -20oC, 
freeze-dried for 2 days at -80oC (BenchTop Pro, VirTis) and stored at -20 oC until further use. 
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3.4. SYNTHESIS OF METHACRYLATED PECTIN 
PectMA was prepared and kindly provided by Rúben Pereira and Filipa Sousa from i3S/INEB 
(detailed protocol to be published elsewhere). 
 
3.5. PREPARATION OF HAMA/PECTMA HYDROGELS 
 3.5.1. PREPARATION OF HAMA/PECTMA HYDROGEL PRECURSOR (PRE-POLYMER) SOLUTIONS AND 
FUNCTIONALIZATION WITH RGD 
Irgacure 2959 (photoinitiator) solutions were prepared at a final concentration of 0.05% (w/v) 
in either 0.9% NaCl (pH 5.5) in deionized water or PBS (pH 8.5) and used to separately dissolve 
HAMA and PectMA. Then, HAMA and PectMA solutions were mixed together at a 1:1 ratio 
yielding final pre-polymer solutions with defined concentrations of each polymer.  
In order to prepare Arg-Gly-Asp (RGD)-functionalized pre-polymer solutions, thiolated RGD 
peptides (CGGGGRGDSP, MW=861.88 gmol-1, Genscript) were dissolved in the pre-polymer 
solutions at final concentrations of 1 mM and 2 mM and allowed to react for 20h at 20oC under 
1400 rpm agitation (Thermomixer comfort, Eppendorf). 
Herein, different pre-polymer concentrations were tested, as described in Table 2. 
 
TABLE 2: COMPOSITION OF PRE-POLYMER SOLUTIONS USED IN THIS WORK. DIFFERENT FORMULATIONS 
WERE PREPARED WITH VARYING HAMA, PECTMA AND RGD CONCENTRATIONS. 
HAMA % (w/v) PectMA % (w/v) RGD (mM) Dissolved in 0.05% Irgacure in 
0.125 
0.125 0 0.9% NaCl 
0.25 
0.75 
1.5 
0.75 
0 
0 0.9% NaCl 0.125 
0.25 
0.75 0.125 
0 
PBS pH 8.5 1 
2 
       
 
 
3.5.2.  FABRICATION OF HAMA/PECTMA HYDROGELS 
Hydrogel disks composed of a mixture of HAMA and PectMA were prepared by 
photocrosslinking with ultraviolet (UV) radiation. For each disk, 35 μl of pre-polymer solution 
was transferred to a polytetrafluoroethylene (PTFE) surface (Figure 5 a) and compressed with a 
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glass slide using a 750 μm spacer (Figure 5 b). UV light (Blue Wave 200, Dymax) intensity under 
the slide was calibrated (Accu-cal®-30, Dymax) to 7 mW/cm2 and then applied to pre-polymer 
solutions for 60 seconds (Figure 5 (b)). The glass slide was then carefully removed from the 
surface and disks were detached using a spatula. 
 
Figure 5: Preparation of HAMA/PectMA hydrogels (a) pre-polymer solutions were pipetted over a PTFE 
surface, (b) pre-polymer were photocrosslinked using UV light. 
3.6. PHYSICOCHEMICAL CHARACTERIZATION OF DEVELOPED HYDROGELS 
3.6.1.  1H NMR CHARACTERIZATION OF HYDROGEL PRECURSOR (PRE-POLYMER) SOLUTIONS 
Methacrylation efficiency was evaluated by 1H Nuclear magnetic resonance (NMR). HAMA was 
dissolved in deuterium oxide (2H2O) (Sigma) overnight with agitation (4oC, 1400 rpm) at a 
concentration of 0.5% (w/v). 1H NMR spectra were then recorded at 70oC using an NMR 
spectrometer (Bruker Avance III, Bruker). 
Methacrylation efficiency of PectMA was evaluated according to a detailed protocol (to be 
published elsewhere). 
 3.6.2. RHEOLOGICAL EVALUATION (SHEAR MODULI) 
The rheological behaviour of hydrogels was evaluated using a Kinexus Pro rheometer (Malvern 
Instruments, Malvern, UK). Hydrogel disks were prepared from 35 μl of precursor solution with 
a 750 μm initial height (distance from the PTFE surface to the glass slide) defined by a spacer 
and incubated at 37oC in 500 μl Dulbecco's Modified Eagle Medium-HEPES (DMEM-HEPES, 
Sigma) supplemented with 10% Fetal Bovine Serum (FBS) in wells of 24-well plates. After 1 and 
3 days of incubation, disks were removed from the wells, punched into cylinders with 4 mm 
diameter, placed between parallel plate geometries of the rheometer and compressed to 80% 
of their height. Shear elastic modulus was evaluated by frequency sweep tests at 37oC in a 
water-vapour saturated environment with constant 1% strain from 0.01-10 Hz. 
3.7. PREPARATION OF CELL-LADEN HAMA/PECTMA HYDROGELS 
3.7.1. CELL CULTURE  
Human Dermal Neonatal Fibroblasts isolated from foreskins of healthy male newborns 
(HDNFs, Zenbio) were cultured in Dulbecco’s Modified Eagle Medium high glucose, 
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GlutaMAX™, 110 mg/L sodium pyruvate (31966, Gibco) supplemented with 10% (v/v) Fetal 
Bovine Serum (FBS, 10270, Gibco), 1% (v/v) Penicillin/Streptomycin (Biowest), 1% (v/v) 
Amphotericin B (Capricorn Scientific). Cells were maintained at 37oC, 5% CO2 atmosphere in a 
humidified incubator and trypsinized (0.05% trypsin/EDTA solution) at 90% confluence. For all 
experiments, fibroblasts were used at passages 5-9. 
 
3.7.2. CELL ENTRAPMENT WITHIN HAMA/PECTMA HYDROGELS 
Hydrogel pre-polymer solutions were prepared as described above, pre-warmed at 37oC and 
HDNFs were suspended in those solutions at a final cell density of 107 cells/mL. 
Cell-laden pre-polymer solutions were then photopolymerized into 20 μL hydrogel disks using 
a 500 μm spacer. Disks were then transferred to 24-well plates, immersed in 500 μL of 
complete DMEM and cultured in a humidified incubator at 37oC, 5% CO2. Medium was 
refreshed after 1 hour and every 3 days in culture. Cell viability and synthesis of extracellular 
matrix (ECM) components were then evaluated up to 7 days in culture. 
 
3.8. BIOLOGICAL CHARACTERIZATION OF CELL-LADEN HYDROGELS 
 3.8.1. EVALUATION OF CELL-LADEN HYDROGEL DISK AREA 
Hydrogel area was evaluated by image analysis. In brief, culture medium was removed from 
wells containing hydrogel disks after 1, 3, and 7 days in culture and images of the disks were 
recorded with 0.63x magnification using a stereo microscope (SZX16, Olympus). Disk area was 
then measured using FIJI software (ImageJ 1.51d). 
 
3.8.2. CELL-LADEN HYDROGEL DISSOLUTION AND CELL RETRIEVAL 
Hydrogel matrices were washed with PBS, transferred to individual Eppendorf tubes and 
dissolved by incubation with a 1000 U/mL hyaluronidase (Sigma), 50 U/mL pectinase (Sigma), 
2.5% (w/v) trypsin 5 mM EDTA solution in PBS for 5 minutes or until dissolved at 37oC under 
1400 rpm agitation (Thermomixer comfort, Eppendorf). After hydrogel dissolution, cell 
suspensions were centrifuged at 10 000 rpm for 5 minutes. Supernatants were discarded and 
cell pellets were washed with 500 μL PBS and centrifuged twice (10 000 rpm, 5 minutes). After 
the final centrifugation, cells were re-suspended in PBS, counted using a Neubauer chamber 
and cell numbers per hydrogel were determined. 
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3.8.3. EVALUATION OF CELL METABOLIC ACTIVITY (RESAZURIN REDUCTION ASSAY) 
Cell metabolic activity was evaluated using the Resazurin-reduction assay after 1, 3 and 7 days 
in culture. Hydrogels were transferred to wells of 24-well plates containing 500 μL of complete 
DMEM with 20% (v/v) resazurin (Sigma) and incubated for 2h at 37oC, 5% CO2 in a humidified 
incubator. Then, medium was transferred to wells of a black 96-well plate (100 μL/well) and 
fluorescence was recorded (530 nm λex, 590 λem) using a microplate reader (Synergy Mx, 
BioTek). Fluorescence levels were then normalized for the number of cells retrieved from each 
hydrogel after dissolution.  
 
 3.8.4. EVALUATION OF CELL VIABILITY BY LIVE/DEAD ASSAY 
After incubation for 1, 3, and 7 days, hydrogel disks were transferred to wells of a 24-well plate 
containing 500 μL of 2 μg/mL Calcein (Invitrogen), 2.5 μg/mL Propidium Iodide (Sigma) solution 
in TBS for 30 minutes. Then, disks were washed twice in TBS and observed under a confocal 
microscope (Leica TCS-SP5 AOBS, Leica Microsystems), using laser wavelengths of 488 nm 
(green) and 561 nm (red). Live cells were stained green and dead cells stained red. 
 
 3.8.5. CHARACTERIZATION OF CELL PHENOTYPE AND ECM PRODUCTION BY 
IMMUNOCYTOCHEMISTRY 
For evaluating cell cytoskeleton, F-actin distribution was stained using the conjugated probe 
phalloidin/Alexa Fluor® 488 (Molecular Probes-Invitrogen, 1:40). For assessing ECM synthesis 
and deposition, rabbit anti-fibronectin (f3648, Sigma, 1:400) primary antibody was used. Goat 
anti-rabbit Alexa Fluor® 594 F(ab’)2 fragment (Molecular Probes-Invitrogen, 1:1000) was used 
as secondary antibody. All antibodies were diluted in 1% (w/v) bovine serum albumin (BSA) in 
7.5 mM CaCl2 in TBS. After being cultured in HAMA/PectMA hydrogels for 1, 3 and 7 days, cell-
laden hydrogels were washed twice with 7.5 mM CaCl2 in TBS, fixed with 4% (v/v) 
paraformaldehyde (Electron Microscopy Sciences) in TBS for 20 minutes, washed twice again 
and kept at 4oC. Cells were then permeabilized by incubation with 0.1% (v/v) Triton X-100 in 
7.5 mM CaCl2 in TBS, washed 3 times with 7.5 mM CaCl2 in TBS, blocked with 1% (w/v) BSA in 
7.5 mM CaCl2 in TBS for 1h and incubated with primary antibody at room temperature for 4h. 
Samples were then washed 3 times with 7.5 mM CaCl2 in TBS and incubated with secondary 
antibody and Phalloidin/Alexa Fluor® 488 in 1% BSA for 45 minutes. After washing 3 times with 
7.5 mM CaCl2 in TBS, cell nuclei were counterstained with Vectashield mounting medium with 
4’,6-diamino-2-phenylindole dihydrochloride (DAPI) (H-1200, Vector) before visualization using 
a confocal microscope (Leica TCS-SP5 AOBS, Leica Microsystems). 
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3.9.   STATISTICAL ANALYSIS 
Quantifications are expressed as mean ± standard error mean (SEM). A difference between 
experimental groups was considered significant with a 95% confidence interval whenever 
p<0.05. For comparisons between hydrogel formulations and timepoints, the two-way ANOVA 
statistical test was applied. 
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CHAPTER 4: RESULTS AND DISCUSSION 
4.1. PREPARATION OF HAMA/PECTMA HYDROGEL PRECURSOR (PRE-POLYMER) 
SOLUTIONS 
Hyaluronic acid (HA) is a biocompatible, biodegradable and viscoelastic non-sulfated 
glycosaminoglycan composed of D-glucuronic acid and N-acetyl-D-glucosamine (Figure 6a) 
[128,129]. It is an ECM component biodegradable by hyaluronidase and its high abundance in 
skin makes this organ its largest reservoir in the body [130,131]. HA exists in both dermis and 
epidermis [132] and provides binding sites for CD44, a molecule expressed by cells such as 
fibroblasts [133]. Even though it is abundant in natural tissues, one major advantage of HA is 
that it can be produced using bacteria (e.g. Streptococci or Bacillus subtilis) by fermentation or 
direct isolation, allowing the generation of large material quantities in a reproducible way 
[132,134].  
 
 
Figure 6:  (a) hyaluronic acid chemical structure [135] (b) pectin chemical structure and coordination 
with Ca2+ ions [136] 
Pectin (Figure 6b), on the other hand, is a polysaccharide composed of alternating α-L-(1-4)-
guluronate residues and α-D-galacturonate residues [137]. Low-methoxyl pectins form gels in 
the presence of Ca2+ [136], as they are able to coordinate divalent cations forming “egg-box” 
molecular structures [137] which allows this material to form hydrogels via internal [138] or 
external [139] gelation mechanisms. 
Herein, both polymers were methacrylated in order to make them photocrosslinkable and 
mixed to form pre-polymer solutions that would benefit from both UV crosslinking by free 
radical polymerization and external gelation of PectMA by calcium coordination. 
 
4.1.1. METHACRYLATION OF HA 
In order to create a covalently photocrosslinkable two-polymer hydrogel system, HA was 
modified through a reaction with methacrylic anhydride. This reaction of unmodified HA with 
methacrylic anhydride under alkaline conditions is one of the simplest processes used for the 
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modification of HA [140]. Methacrylate-modified materials have been receiving great attention 
in the field of tissue engineering, owing to their overall good cytocompatibility [141,142] as 
well as adjustable mechanical properties [143]. This modification generates photocrosslinkable 
materials through the addition of methacrylate moieties to the polymer backbone, which react 
upon exposure to a light source (UV light in the present work), establishing bonds that connect 
adjacent molecules within a polymeric matrix. Several factors can affect the efficiency of the 
methacrylation reaction, including the reaction time, as well as the excess amount of MA and 
the molecular weight of the unmodified (initial) polymer [126,142].  
Herein, HA modification was confirmed by 1H-NMR spectroscopy. The spectrum obtained for 
HAMA (FIGURE 7) displayed the characteristic peaks of the two protons of the double bond 
region of MA (δ 5.75-6.19 ppm), which are absent in the unmodified HA. The degree of 
methacrylation of HAMA was calculated as the ratio between the relative peak integrations of 
methacryloyl group protons (δ 5.75-6.19 ppm) and HA methyl protons (δ 2 ppm) and 
determined to be 8% (Figure 7). 
 
 
Figure 7: NMR spectrum of HAMA. 
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4.2. HYDROGEL FORMATION AND CHARACTERIZATION 
4.2.1. INFLUENCE OF PECTMA AND HAMA CONCENTRATIONS AND RATIOS 
In order to preliminarily screen the influence of PectMA content on hydrogel properties and to 
define hydrogel mixture concentrations to be further studied, hydrogel formulations of varying 
PectMA concentrations ranging from 0% to 1.5% were evaluated after overnight incubation at 
37oC in DMEM-HEPES. For this purpose, hydrogels were produced with a constant 
concentration of HAMA (0.75%, w/v) and the shear elastic moduli (G’) of different 
formulations were assessed. The obtained samples exhibited a range of G’ from less than 100 
Pa to more than 1.5 kPa, increasing with higher PectMA content (Table 3).  
 
Table 3: Preliminary assessment for the optimization of % PectMA in hydrogel disks. 
HAMA % (w/v) PectMA % (w/v) G’ (Pa) 
0.75 
0 68 
0.5 709 
1.5 1521 
 
Hydrogel moduli are able to Fibroblast ability to spread and proliferate is influenced by matrix 
stiffness, as networks with high moduli (>1 kPa) can act as a physical barrier to cells which is 
not evident in softer formulations [144]. Indeed, for hydrogels with shear moduli ranging from 
50 to 1200 Pa, fibroblast morphology has been reported to be radically altered, with cell 
spreading being promoted in hydrogels with lower modulus and inflammatory pathways being 
triggered for cells cultured in stiffer matrices [145]. Compliant matrices with moduli ≤120 Pa 
have also been shown to promote cell proliferation and lead to mesenchymal stem cell 
aggregation [146]. As formulations with increasing concentrations of PectMA (0.5 and 1.5%, 
w/v) rendered matrices stiffer, and in order to produce hydrogels with low G’, the influence of 
% PectMA between 0% and 0.25% was further evaluated using lower PectMA concentrations, 
in the range of 0% to 0.25% after 1 and 3 days of incubation at 37oC in DMEM-HEPES 
supplemented with 10% FBS. Here, a significant increase in G’ values was observed with 
increased % PectMA in all three formulations analysed (0, 0.125 and 0.25% PectMA with 
constant 0.75% HAMA, Figure 8), which shows a strong dependency of this property on the 
PectMA content of the hydrogels. Moreover, for hydrogels with the highest PectMA content 
(0.25%), a significant increase in G’ was noticeable between day 1 and day 3. 
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The observed stiffening of hydrogels with higher PectMA concentrations might be due to the 
fact that besides being able to polymerize by covalently linking methacrylate moieties, this 
polymer is also able to coordinate Ca2+ [147,138] ions that are also present in culture medium. 
The medium used contains 1.8 mM calcium chloride, according to the manufacturer. The ionic 
crosslinking promoted by Ca2+ leads to a secondary gelation process that might occur in a 
longer timeframe than the initial photocrosslinking. These results suggest that for higher 
PectMA concentrations the hydrogel system might take longer than 1 day to stabilize in culture 
medium, whereas for lower PectMA concentration this phenomenon is no longer noticeable.  
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Figure 8: Effect of % PectMA on shear elastic modulus after 1 and 3 days of incubation in DMEM-HEPES 
with 10% FBS. Legend: symbols denote statistically significant differences (p<0.05) from 0% PectMA (#), 
0.125% PectMA (%), day 1 (*), n=4 
Furthermore, in order to investigate the influence of HAMA on the mechanical behaviour of 
developed hydrogels, disks were fabricated with HAMA content ranging from 0.125% to 1.5%, 
while keeping PectMA constant at 0.125%.  
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Figure 9: Effect of % HAMA on shear elastic modulus after 1 and 3 days of incubation in DMEM-HEPES 
10% FBS. Legend: symbols denote statistically significant differences (p<0.05) from 1.5% HAMA (*), 
0.75% HAMA (#), n=4 
Similar to what happened when %PectMA was increased, higher HAMA content in pre-polymer 
solutions led to hydrogels with higher G’ (Figure 9). By day 1, G’ values varied between 68 and 
264 for the lowest (0.125% HAMA) and the highest (1.5% HAMA) concentrations of HAMA, 
respectively. However, modifying %HAMA resulted in no noticeable G’ variations from day 1 to 
day 3, in opposition to observations made when increasing PectMA content from 0.125% to 
0.25%. Indeed, a slight increase in PectMA led to a more than double G’ after 3 days of 
incubation (Figure 8) while an increase of 0.75% HAMA resulted in stable hydrogels with no G’ 
variations between the two timepoints (Figure 9). 
HAMA content is known to have an influence in hydrogel mechanical properties as both 
compressive and shear moduli have been shown to increase with increasing concentrations 
[143,148]. This higher shear modulus has been suggested to be due to a higher density of 
crosslinks within the polymeric network [148]. Indeed, using this system, a range of hydrogel 
formulations could be prepared with tuneable moduli by varying polymer concentrations and 
ratios. In addition, as HA and pectin solutions often present distinct viscosity levels, with 
hyaluronic acid [149] being more viscous than pectin [150], viscosity could possibly become 
tuneable by adjusting the aforementioned parameters. 
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4.2.3.  INFLUENCE OF THE SOLUTION USED TO PREPARE PRE-POLYMER SOLUTIONS 
In order to modify methacrylated polymers with thiolated RGD at a basic pH [151,152], pre-
polymer solutions were prepared at pH 8.5 in PBS and properties of the resulting hydrogels 
were compared with the ones of disks fabricated at pH 5.5 0.9% NaCl solutions. Herein, the 
influence of the two solutions used for dissolving both PectMA and HAMA on the shear elastic 
moduli of the developed hydrogels was evaluated. After 1 and 3 days of incubation at 37oC in 
DMEM-HEPES supplemented with 10% FBS, slightly higher moduli were observed in hydrogels 
prepared with PBS (Figure 10). However, no significant differences were noticeable between 
the two formulations at each time point or between the two timepoints for each formulation, 
supporting earlier observations and showing that hydrogels containing 0.75% HAMA and 
0.125% PectMA are stable in culture medium over time. 
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Figure 10: Influence of solvent on shear elastic modulus of hydrogel disks incubated in DMEM-HEPES 
10% FBS at 37oC for 1 and 3 days, n=4 
4.2.4. INFLUENCE OF RGD MODIFICATION 
After obtaining a hydrogel system with adequate mechanical properties and stability in culture 
medium, pre-polymer solutions were modified with RGD peptides in order to promote cell 
adhesion [138,153]. Modifications of HA [154–156]  and pectin [138,150] with RGD peptides 
have been described in the past using different protocols. However, as both polymers used 
herein had been previously modified with methacrylate moieties, a Michael-type addition 
reaction was conducted between thiolated RGD peptides and methacrylates. This type of 
reaction takes place between nucleophilic Michael donors (e.g. thiols of thiolated RGD 
peptides) and Michael acceptors (e.g. methacrylate groups of HAMA and PectMA) [157]. 
Considering that methacrylate groups are known to show slower reaction rates than other 
moieties such as acrylates [157], reaction was conducted for 20 hours at an alkaline pH (8.5). 
The high pH level is important to enhance reaction kinetics by increasing thiol deprotonation in 
solution [152,158,159], promoting the reaction with the Michael acceptor. Moreover, as pre-
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polymer solutions were photopolymerized with UV light, thiol deprotonation by free radicals 
and further reaction with the polymer chains was also expected to occur [160].  
Indeed, hydrogels containing RGD peptides were successfully fabricated with final RGD 
concentrations of 1 and 2 mM and shear elastic moduli were evaluated after 1 and 3 days of 
incubation in culture medium (Figure 11). 
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Figure 11: Influence of RGD modification on shear elastic modulus of hydrogel disks incubated in 
DMEM-HEPES with 10% FBS at 37oc for 1 and 3 days. Legend: symbols (*) denote statistically significant 
differences (p<0.05), n=4 
After incubation in DMEM-HEPES 10% FBS for 1 day, hydrogels containing 2 mM RGD exhibited 
higher stiffness levels when compared with gels with no modification (Figure 11). However, 
this difference was no longer noticeable after 3 days. These results suggest that the amount of 
methacrylate groups that reacted with RGD peptides was not enough to inhibit hydrogel 
photopolymerization or decrease its stiffness by reactive site occupation. Indeed, RGD 
functionalization of hydrogels by Michael addition reaction has been reported to result in 
hydrogels with similar mechanical properties [161,162], whereas pectin hydrogels 
functionalized with RGD by carbodiimide chemistry have shown increased shear moduli [138]. 
Overall, the modification of the polymers used herein through the addition of RGD peptides 
did not result in significant alterations of the matrix stiffness, supporting the use of the 
material concentrations proposed above (0-0.125 %PectMA and 0.125-1.5 % HAMA) for the 
entrapment of fibroblasts and further evaluation of the biological performance of the system. 
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4.3. IN VITRO CELL BEHAVIOUR 
4.3.1. CELL NUMBERS WITHIN HYDROGEL MATRICES 
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Figure 12: Cell numbers within each hydrogel disk after 1, 3 and 7 days in culture as a function of (a) 
%PectMA, with constant 0.75% HAMA (w/v); (b) %HAMA, with constant 0.125% PectMA (w/v) Legend: 
Symbols denote statistically significant differences (p<0.05) from different timepoint (*), 0.125% HAMA 
(#), 0.25% HAMA (%), n=3 
The presence of encapsulated cells had a noticeable influence on hydrogel behaviour, as it was 
only possible to evaluate the number of cells encapsulated in hydrogels composed only of 
0.75% HAMA (0% PectMA) on day 1. Soon after, these hydrogels without pectin started losing 
their integrity, making it impossible to adequately transfer them to Eppendorf tubes and 
quantify the cell number after 3 and 7 days in culture. Interestingly, all formulations composed 
of a mixture of HAMA and PectMA kept their integrity for the whole duration of the 
experiment, showing that the presence of PectMA is necessary, even at low concentrations 
(i.e. 0.125%), to keep the integrity of 0.75% HAMA hydrogel disks in culture for 7 days. Yet, for 
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formulations that kept their integrity with 0.75% HAMA, a further increase in PectMA content 
from 0.125% to 0.25% did not have a noticeable effect on the number of cells retrieved from 
the matrices and cell numbers were kept approximately constant throughout the 7 days 
(Figure 12 (a)). It is worth to mention, however, that a notable increase of shear elastic 
modulus was verified on hydrogels containing 0.125% PectMA when compared with 
formulations composed only of 0.75% HAMA, which might have been crucial to allow gel 
stability in culture. Indeed, hydrogels composed only of HAMA are expected to establish 
covalent bonds only between methacrylate moieties of HAMA chains whereas by adding 
PectMA, links not only between methacrylates of the same polymer but also between HAMA 
and PectMA are likely to occur. Moreover, as PectMA is able to undergo crosslinking by Ca2+ 
ions present in culture medium, a secondary stiffening is expected to contribute to higher 
overall hydrogel integrity. Therefore, the existence of two crosslinking steps may constitute an 
explanation for the reinforcement of the developed HAMA/PectMA hydrogels, which exhibit a 
better stability in aqueous environment over time, as observed herein. 
On the other hand, increasing the amount of HAMA seems to lead to an increase in the 
number of cells entrapped within the hydrogel matrix on day 1, with significantly higher cell 
numbers on hydrogels with higher HAMA content (Figure 12 b). When comparing the 
behaviour of formulations with increasing HAMA content over time during the 7 days of 
culture, no common trend was noticeable regarding the number of cells retrieved. Indeed, the 
cell content of formulations containing 0.125% HAMA was approximately constant, while 
hydrogels containing 0.25% HAMA and 0.75% showed an increase in the number of 
encapsulated cells. Moreover, the formulations containing 1.5% HAMA exhibited a decrease in 
cell number after 3 days in culture which was followed by an increase on day 7. Overall, the 
highest cell number was registered in the formulation with the highest concentration of HAMA 
(1.5%), after 1 day.  
Interestingly, for some formulations (0.75% HAMA, 0% PectMA; 0.75% HAMA, 0.25% PectMA; 
1.5% HAMA, 0.125% PectMA), the number of cells counted after hydrogel dissolution was 
slightly higher than the initial number of cells loaded onto the hydrogel disks. This might be 
related to either cell embedding, disk dissolution or cell counting protocols. Even though 
several measures were implemented in order to minimize sources of error, factors such as the 
presence of small bubbles in the cell suspension mixed with pre-polymer solutions might have 
contributed to these unexpected results by respectively increasing the cell concentration in the 
hydrogels or leading to an overestimation of cell numbers. A possible alternative to this 
protocol would be to quantify total DNA content within using the Quant-it™ PicoGreen® 
36 
 
dsDNA assay kit (Invitrogen). Unexpectedly, cell number retrieved from hydrogels containing 
0.25% HAMA / 0.125% PectMA on day 1 were lower when compared to other formulations 
with either higher or lower HAMA content. 
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Figure 13: Cell numbers within each hydrogel disk after 1, 3 and 7 days in culture as a function of RGD 
concentration. Legend: Symbols denote statistically significant differences (p<0.05) from 1 mM RGD (*), 
day 1 (#), day 3 (%), n=3  
Furthermore, cellular content was also assessed in RGD-modified hydrogels. After 1 day of 
culture, no differences were observed between non-functionalized hydrogel matrices and 
RGD-modified hydrogels. Nonetheless, functionalization of hydrogel formulations with RGD 
peptides led to an increase in cell numbers observed on day 7, which was not verified for cells 
cultured in non-functionalized hydrogel matrices (Figure 13). This suggests that cells cultured 
on RGD-functionalized hydrogels might preserve their proliferative capacity over time in 
culture. 
4.3.2. DISK AREA VARIATION OVER TIME 
In order to evaluate the effect of cells cultured on different hydrogel matrices on disk 
macroscopic integrity, hydrogel area was observed and measured after 1, 3 and 7 days in 
culture for varying % PectMA (Figure 14) and % HAMA (Figure 15). Hydrogel disks made out of 
non-functionalized polymers showed no considerable area variations with increasing time in 
culture. However, an increase in polymer content, particularly HAMA, led to higher disk areas, 
noticeable since day 1.  
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Figure 14: Macroscopic view of cell-laden HAMA/PectMA hydrogels with varying %PectMA after 1, 3 and 
7 days in culture. Scale bar = 5 mm. 
 
Figure 15: Macroscopic view of cell-laden HAMA/PectMA hydrogels with varying %HAMA after 1, 3 and 
7 days in culture. Scale bar = 5 mm 
38 
 
D
a
y
 1
D
a
y
 3
D
a
y
 7
0
1 0
2 0
3 0
4 0
A
r
e
a
  
(m
m
2
)
0 %  P e c tM A
0 .1 2 5 %  P e c tM A
0 .2 5 %  P e c tM A
&
D
a
y
 1
D
a
y
 3
D
a
y
 7
0
1 0
2 0
3 0
4 0
A
r
e
a
  
(m
m
2
)
0 .1 2 5 %  H A M A
0 .2 5 %  H A M A
0 .7 5 %  H A M A
1 .5 %  H A M A
*
#
*
#
*
#
%*
#
*
#
*
b )
a )
 
Figure 16: Influence of polymer concentration on cell-laden hydrogel disk area (a) variation of PectMA 
content with 0.75% HAMA; (b) variation of HAMA content with 0.125% PectMA. Legend: symbols 
denote statistically significant differences (p<0.05) from 0% PectMA (&), 0.125% HAMA (*), 0.25% 
HAMA (#), 0.75% HAMA (%), n=3 
However, contrarily to the behaviour of hydrogels made solely out of methacrylated polymer 
mixtures, the functionalization of 0.75% HAMA/0.125% PectMA formulations with RGD 
peptides led to a contraction of the hydrogel matrix after being cultured with cells, as 
noticeable by a decrease in disk area after 3 and 7 days (Figure 18). Even though hydrogel 
contraction was present in all three formulations (0 mM, 1 mM and 2 mM), a significantly 
lower disk area was noticeable after 3 days in culture in 2 mM RGD disks, whereas it was only 
observable after 7 days in 0 mM and 1 mM formulations. Nevertheless, hydrogel disks 
functionalized with 1 and 2 mM RGD and cultured with HDNFs for 7 days displayed an area of 
37% and 17% of day 1, whereas non-functionalized gels remained with 71% of initial area over 
time in culture. 
Indeed, matrix contraction has already been described for different RGD-functionalized 
polymers [144,138,163] such as pectin hydrogels with similar shear moduli [138]. Indeed, as 
RGD peptides are known to bind integrins [164,165] and contractile forces exerted by cells in 
culture are transferred to the surrounding matrix through transcellular adhesions such as 
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these [166], the observed decrease in surface area might have been a result of matrix 
contraction triggered by this phenomenon. Moreover, as area variation was higher and 
noticeable earlier for formulations modified with higher RGD concentrations (2 mM), reaction 
with increased amounts of peptide might have resulted in an increase in number of 
functionalized moieties, leading to a higher number of cell adhesive sites and consequently 
higher matrix contraction.  
 
Figure 17: Macroscopic view of cell-laden HAMA/PectMA hydrogels with varying RGD content after 1, 3 
and 7 days in culture. Scale bar = 5 mm. 
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Figure 18: Influence of the incorporation of RGD peptide on disk area legend: symbols denote 
statistically significant differences (p<0.05) from day 1 (*), day 3 (#), n=3.  
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4.3.3. CELL METABOLIC ACTIVITY (RESAZURIN REDUCTION ASSAY) 
HDNF metabolic activity was evaluated after 1, 3, and 7 days using the resazurin reduction 
assay and normalized for cell number within each hydrogel. After 1 day in culture, no 
differences were noticeable between cells cultured in hydrogels with varying concentrations of 
one of the polymers in the mixture while keeping the other constant. Differences between 
formulations at the same timepoint were only observed on day 3 for disks with different 
HAMA content. Here, cells encapsulated in hydrogels composed of 0.75% HAMA exhibited the 
highest values of metabolic activity, followed by the formulations with 1.5% HAMA. Cells 
encapsulated in 0.125% HAMA exhibited the lowest metabolic activity values. However, after 7 
days, a significant decrease in metabolic activity was observed for all formulations when 
compared to values of day 1.  
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Figure 19: Metabolic activity of cells embedded in HAMA/PectMA hydrogels of (a) 0.125% PectMA, with 
varying %HAMA; (b) 0.75% HAMA, with varying %PectMA. Data for 0% PectMA formulations not shown 
as hydrogel disks lost integrity after 3 days in culture. Legend: symbols denote statistically significant 
differences (p<0.05) between different formulations (*), from day 1 (#), from day 3 (%), n=3.  
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For RGD-functionalized hydrogels, a similar behaviour to non-modified formulations was 
found, with cell metabolic activity decreasing with longer culture times, but with no significant 
differences among the three formulations studied (Figure 20). Indeed, a decrease in number of 
metabolically active cells has already been reported after fibroblast entrapment in RGD-
functionalized hydrogels that occurred along with hydrogel matrix contraction after day 3 
[163]. 
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Figure 20: Metabolic activity of cells embedded in HAMA/PectMA hydrogels of 0.125% PectMA, 0.75% 
HAMA functionalized with RGD peptides. Legend: Symbols denote statistically significant differences 
(p<0.05) from day 1 (#), from day 3 (%), n=3. 
4.3.4. CELL VIABILITY (LIVE/DEAD ASSAY) 
Live/Dead evaluation of cells embedded in HAMA/PectMA hydrogels revealed that most cells 
remained viable over time in culture both for hydrogels containing varying PectMA (Figure 21) 
or HAMA (Figure 22) content. Hydrogels containing either 0% or 0.125% PectMA seem to lead 
to cell clustering on day 3 whereas for 0.25% PectMA that phenomenon is less noticeable and 
only starts to be apparent on day 7. Indeed, higher PectMA content leads to hydrogels with 
higher shear elastic moduli, possibly hindering cell mobility within the matrix. As polymers not 
functionalized with RGD were used herein, cells were not able to attach to the matrix and kept 
a rounded morphology throughout the 7 days in culture. As fibroblasts are adherent cells and 
hydrogels with lower PectMA content did not seem to limit cell mobility, cells were able to 
form clusters and possibly establish cell-cell adhesions, as an anchorage support within the 
hydrogel matrix. . 
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Figure 21: Viability of HDNFs cultured in HAMA/PectMA hydrogel disks for 1, 3 and 7 days with varying 
PectMA content. Live cells are stained green by Calcein AM and dead cells red by Propidium Iodide. 0% 
PectMA hydrogels not shown due to loss of integrity before day 7. Scale bar: 250 μm. 
When increasing % HAMA, formulations with lower polymer content appeared to have a 
higher cell density (Figure 22), which might be due to the fact that these disks exhibited lower 
dimensions when compared with formulations with higher polymer content (Figure 16). 
Indeed, even though lower cell numbers were retrieved from gels with lower HAMA content 
(Figure 12), smaller dimensions might have been sufficient to lead to an apparently higher cell 
density. In addition, hydrogels with lower HAMA content seem to contain greater amounts of 
dead cells (stained red on Figure 22). These formulations contained very low polymer 
concentration that were possibly not optimal to sustain cells in culture for prolonged periods 
of time. 
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Figure 22: Viability of HDNFs cultured in HAMA/PectMA hydrogel disks for 1, 3 and 7 days with varying 
HAMA content. Live cells are stained green by calcein AM and dead cells red by propidium iodide. Scale 
bar: 250 μm. 
 
Figure 23: viability of HDNFs cultured in HAMA/PectMA hydrogel disks for 1, 3 and 7 days with varying 
RGD content. Live cells are stained green by calcein am and dead cells red by propidium iodide. Scale bar 
= 250 μm. Note: 1 mM day 7 micrograph pictures a fragment of the cultured hydrogel. 
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Hydrogel functionalization with RGD peptides resulted on similarly high cell viability for the 
three formulations, with the majority of cells staining green throughout the 7 days in culture, 
supporting that 0.75% HAMA / 0.125% PectMA hydrogels are able to maintain encapsulated 
cells with a high viability upon entrapment and over time in culture. 
4.3.5. CYTOSKELETON AND MATRIX PRODUCTION (IMMUNOCYTOCHEMISTRY) 
After being cultured for 1, 3, and 7 days, cells were stained for F-actin and fibronectin in order 
to evaluate cell morphology and cytoskeleton, and matrix deposition.  
When cultured inside hydrogels containing 0.75% HAMA with increasing PectMA content, cells 
exhibited a round morphology on day 1, becoming slightly more elongated after 7 days in 
culture, particularly in hydrogels with 0.125% PectMA.  
In addition, for hydrogels with low to no PectMA content (0% and 0.125%) and lower shear 
elastic moduli, cells appear to form clusters on day 3. However, for longer culture periods, 
disks composed of HAMA in the absence of PectMA (0%) lost their integrity before day 7, while 
disks containing PectMA (0.125%) kept their integrity. In this latter formulation, cells 
presented a more elongated morphology, which was less noticeable when PectMA content 
was doubled to 0.25% (Figure 24). Indeed, the presence of PectMA seemed to be necessary to 
keep the integrity of cell-loaded 0.75% HAMA hydrogels in culture over time and has a clear 
influence on cell morphology. Indeed, modification by reaction with MA generates 
photocrosslinkable pectin, which reticulates upon exposure to UV light. In addition, as pectin is 
known to be able to form hydrogels by internal [138] or external gelation [139], this polymer  
might still be able to coordinate Ca2+ ions after photopolymerization, providing cell-laden 
hydrogels with structural stability and preventing its disruption triggered by cells.  
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Figure 24: HDNFs embedded in HAMA/PectMA hydrogels with 0.75% HAMA and increasing % PectMA, 
stained for F-actin (green), fibronectin (red) and nuclei (blue). 0% PectMA hydrogels not shown due to 
loss of integrity before day 7. Scale bar: 100 μm. 
Additionally, in order to evaluate the influence of HAMA, cell-laden hydrogels containing 
0.125% PectMA and increasing HAMA content were fabricated (Figure 25). Disks produced 
with low HAMA content (0.125%) appear to promote an increase in cell density within the 
matrix, observable as a higher number of cells per area (Figure 25), possibly as a consequence 
of smaller disk dimensions, as macroscopically observed (Figure 14). Accordingly, increasing 
the HAMA content of hydrogels disks seems to lead to lower cell densities (Figure 25). Indeed, 
whereas hydrogels with different PectMA content exhibited similar dimensions in culture, 
increasing HAMA concentration resulted in the fabrication of hydrogel disks that appeared 
larger after 1 day (Figure 16), even though all disks were initially fabricated with the same 
volume of pre-polymer solution. Therefore, and due to the fact that cells were embedded in 
the hydrogels as a homogeneous suspension and no cell-adhesive motifs were present in the 
matrix, cells may have been further separated from each other within the network during the 
first day in culture as hyaluronic acid is able to absorb a high quantity of water as a result of 
the presence of negative charges [128]. 
Regarding fibronectin deposition, this protein was mostly located around cells, with no major 
differences being observed among the different formulations produced from non-
functionalized pre-polymer solutions. These results suggest that neither PectMA nor HAMA 
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had a differential ability to modulate cell behaviour, with the hydrogels acting only as reservoir 
of cells. 
 
Figure 25: HDNFs embedded in HAMA/PectMA hydrogels with 0.125% PectMA and increasing % HAMA, 
stained for F-actin (green), fibronectin (red) and nuclei (blue). Scale bar: 100 μm. 
As matrices composed of 0.75% HAMA / 0.125% PectMA enabled cells to move within the 
hydrogel and promoted slightly higher cell spreading when compared with the remaining 
formulations, hydrogels with this composition were further functionalized with RGD peptides, 
molecules known to promote integrin-mediated cell adhesion. 
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Figure 26: HDNFs embedded in HAMA/PectMA hydrogels with 0.125% PectMA, 0.75% HAMA and 
increasing RGD concentration, stained for F-actin (green), fibronectin (red) and nuclei (blue). Scale bar: 
100 μm. 
The modification of hydrogel matrices with RGD peptides led to an increased cell spreading, 
which was detected as soon as 1 day after entrapment for both 1 mM and 2 mM formulations 
and became more evident after 3 and 7 days. By this time, encapsulated cells appeared with a 
more spindle-shaped morphology, possibly establishing cell-cell contacts with time. Moreover, 
a network of fibronectin mostly located around cells was formed and appeared prominently on 
day 7. Indeed, fibronectin is an ECM protein known to be produced by fibroblasts [167] and 
was chosen herein as an example of matrix deposition. In addition, this fibronectin network 
appeared denser in 2 mM hydrogels when compared with 1 mM formulation, due to either 
increased fibronectin production or matrix contraction. Indeed, hydrogels containing 2 mM 
RGD suffered higher and earlier matrix contraction when compared to 0 and 1 mM 
formulations, as visible both macroscopically (Figure 17) and microscopically as a higher 
density of cell nuclei appeared prominently on 2 mM hydrogels on day 7 (Figure 26). 
Nevertheless, hydrogel functionalization with RGD peptides seemed to promote cell 
attachment to the matrix, with cells acquiring an elongated phenotype not very evident in 
non-functionalized matrices, as well as endogenous ECM production. 
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RGD peptides are well known promoters of cell adhesion and spreading [168], as they are 
recognized and bind several types of integrin such as α5β1 and αvβ3 [164]. The strength of cell 
adhesion to RGD-modified substrates has been shown to be higher for increased RGD densities 
[169]. Moreover, these peptides are also able to sustain cell migration, with higher cell speeds 
being observed for higher RGD ligand densities both in 2D [169] and 3D [156]. RGD motifs are 
present in a wide range of proteins such as fibronectin, vitronectin and laminins [164] and are 
commonly used in order to promote cell adhesion to polymers which would not elicit it 
otherwise [170]. Indeed, RGD-modifications have previously been conducted in both 
hyaluronic acid [154–156] and pectin [138,150], as both hyaluronic acid and pectin are unable 
to bind integrins [128]. 
In this work, hyaluronic acid and pectin were methacrylated and the resulting polymers were 
modified with RGD, generating hydrogel matrices with low shear moduli that are capable of 
promoting cell adhesion, matrix contraction and ECM production while keeping its integrity 
and high cell viability for up to 7 days in culture.   
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 CHAPTER 5: CONCLUSIONS AND FUTURE PERSPECTIVES 
This work aimed at fabricating soft, photopolymerizable hydrogels composed of HAMA and 
PectMA to be used as a skin in vitro model for a high-throughput skin organ-on-a-chip device.  
Using UV-induced free radical photopolymerization, hydrogel disks with tuneable shear moduli 
could be produced using different polymer concentrations and ratios. Hence, by increasing 
polymer content, hydrogels with higher moduli were fabricated. This was observed when 
increasing either HAMA or PectMA concentrations.  
Furthermore, the biological performance of the developed hydrogels was herein assessed 
through the entrapment of human dermal neonatal fibroblasts. When cultured with cells, 
hydrogels fabricated with increasing PectMA content were able to sustain culture of HDNFs for 
up to 7 days. However, formulations composed only of 0.75% HAMA (0% PectMA) started 
losing their structural integrity after being cultured for 3 days, whereas the addition of a 
0.125% PectMA was enough to keep the system stable while promoting a slightly more 
elongated cell morphology, visible at 7 days.  
Overall, variations of HAMA content resulted in differences both in terms of hydrogel size in 
culture and of cell distribution and response. Higher polymer concentrations resulted in 
hydrogels with larger area, while increased cell densities were found in hydrogels with lower 
HAMA content. In particular, cell spreading was more evident in hydrogels composed of 0.75% 
HAMA, possibly due to an interplay between hydrogel swelling and mechanical properties of 
the matrix. Nonetheless, these hydrogels could only act as a reservoir of cells, given that 
HAMA and PectMA are relatively inert regarding cell adhesive cues. Therefore, RGD-
functionalized hydrogels were fabricated and exhibited superior performance, allowing cells to 
interact with the hydrogel matrix, which, in turn, led to a contraction of the disks. This 
phenomenon was dependent on RGD concentrations, happening earlier for formulations with 
higher RGD content. In these matrices, cells appeared elongated and spindle-shaped and a 
fibronectin network which was denser for hydrogels with higher RGD content was formed and 
visible after 7 days in culture. Nevertheless, further characterization of RGD functionalization 
reaction and efficiency is still needed to fully understand the system. 
In summary, a two-polymer hydrogel system was produced and characterized both in terms of 
mechanical and cellular behaviour. The use of a dual system allowed to independently vary 
polymer concentrations and ratios, resulting in tuneable mechanical and biological properties 
while keeping shear moduli low and producing soft hydrogels. However, future studies are still 
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necessary in order to evaluate cell culture for longer periods of time and further characterize 
the resulting cellularized constructs. 
Furthermore, the recapitulation of functionally similar to human skin in terms of transdermal 
transport, wound healing and toxicity response constitutes a major challenge to address when 
engineering in vitro skin constructs to be suitable for a skin-on-chip device. Overall, this work 
provided meaningful insight into the mechanical and biological behaviour of a novel 
photopolymerizable two-polymer hydrogel system with potential impact on the development 
of novel high-throughput skin emulative strategies using 3D bioprinting. 
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